Marex Faces Securities Class Action as Firms Urge Investors to Seek Lead Plaintiff by Dec. 8
Filings center on alleged self-dealing OTC trades and intercompany accounting inconsistencies that plaintiffs claim made Marex’s financials unreliable.
Overview
- Multiple plaintiff firms report that a federal securities class action has been filed against Marex Group plc in the Southern District of New York.
- The putative class covers purchases of Marex securities from May 16, 2024 through August 5, 2025, according to the firms’ notices.
- Complaints allege the company sold over-the-counter financial products to itself and recorded inconsistent related-party and intercompany balances, rendering public statements misleading.
- Notices reference an August 5, 2025 NINGI Research report as the catalyst for disclosure, after which Marex’s stock fell 6.2% on heavy trading volume.
- Investors are being solicited on a contingency basis to seek appointment as lead plaintiff by December 8, 2025, with the firms emphasizing that the allegations remain unproven and no class has been certified.